News
-
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration hebdomadaire d'opérations effectuées du 16 au 20 juin 2025
-
COMMUNIQUÉ RÉGLEMENTÉ
Disclosure of transactions in own shares from June 16 to June 20, 2025
-
-
COMMUNIQUÉ DE PRESSE
Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
Biotest AG announces positive phase III trial results for fibrinogen concentrate BT524 in reducing bleeding, with potential regulatory approval in Europe and U.S. pending. Study data to be presented at ISTH 2025 Congress -
-
COMMUNIQUÉ DE PRESSE
Xebra Announces Corporate Update and Correction Notice of Press Release Announcing Grant of Management Cease Trade Order
Xebra Brands announces correction to press release, management changes, warrant extension. Company focuses on cannabis products, global brands, and intellectual property -